Europe Heparin Market By Type, By Application, By Route of Administration, By End Use, By Country, Growth Potential, COVID-19 Impact Analysis Report and Forecast, 2021 - 2027

The Europe Heparin Market is expected to witness market growth of 6.2% CAGR during the forecast period (2021-2027).

The demand for anticoagulants is very high and it is anticipated to boost the overall heparin market. Moreover, the increased healthcare expenditures and growing awareness levels among the patient are the major factors expected to drive the global heparin market over the forecast period.

The growing burden of chronic diseases is the main factor for the growth of the heparin market. As per the World Health Organization, chronic diseases are a massive global challenge for decades and account for almost 60% of all deaths across the globe. The worldwide burden of chronic diseases may reach 57% by the end of 2020.

In the past few decades, it has been reported that there are increasing incidences of venous thrombosis and cardiovascular diseases across the globe including heart attacks and strokes. It is the major factor that is driving the growth of the global heparin market. Moreover, as heparin is used in various surgeries including orthopaedic and heart surgeries, and rise in the number of patients undergoing such surgeries is expected to further boost the growth of the heparin market. Cardiovascular diseases have a direct impact on the heparin market growth.

The demand for heparin is high in European counties. It is due to the increasing adoption of technologically advanced products in the healthcare sector in this region. The increasing number of patients who are suffering from cardiovascular diseases is very high among the region’s population. This will open new growth avenues in the heparin market in this region. The medical infrastructure is very advanced in the UK. The whole population’s medical expenses are covered by the National Health System. It is financed through general taxation and independently-run by the Department of Health. The major cause of death in the UK is due to coronary heart disease (CHD). The use of heparin in the treatment of CHD is increasing exponentially. Thus, it is expected that the demand for heparin will increase in the forecast period and positively contribute to the growth of the market. Although there is a decline in death rates due to cardiovascular disease (CVD) in the UK, rates are still comparatively high than other Western European countries.

The Germany market dominated the Europe Venous Thromboembolism Market by Country 2020, thereby, achieving a market value of $100.2 million by 2027. The UK market is exhibiting a CAGR of 6.7% during (2021 - 2027). Additionally, The France market is poised to grow at a CAGR of 8.2% during (2021 - 2027).

Based on Type, the market is segmented into Low Molecular Weight Heparin, Unfractionated Heparin and Ultra-low Molecular Weight Heparin. Based on Application, the market is segmented into Atrial Fibrillation, Coronary Artery Disease, Venous Thromboembolism, Renal Impairment and Other Applications. Based on Route of Administration, the market is segmented into Subcutaneous and Intravenous. Based on End Use, the market is segmented into Outpatient and Inpatient. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Baxter International, Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Pfizer, Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Ltd., LEO Pharma A/S, and Viatris, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type

• Low Molecular Weight Heparin
• Unfractionated Heparin
• Ultra-low Molecular Weight Heparin

By Application

• Atrial Fibrillation
• Coronary Artery Disease
• Venous Thromboembolism
• Renal Impairment
• Other Applications

By Route of Administration

• Subcutaneous
• Intravenous

By End Use

• Outpatient
• Inpatient

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Companies Profiled

• Baxter International, Inc.
• B. Braun Melsungen AG
• Fresenius SE & Co. KGaA
• Pfizer, Inc.
• Sanofi S.A.
• Teva Pharmaceuticals Industries Ltd.
• Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
• Dr. Reddy’s Laboratories Ltd.
• LEO Pharma A/S
• Viatris, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free